08:30–09:30Industry Symposium
09:30–09:45Scientific Posters and Coffee
09:45–11:00Access to Long Acting Prevention for Key Populations in Low and Middle
Income Countries (LMICs): Making it Work
In collaboration with the International AIDS Society (IAS)
Chairs:Anton Pozniak, Chelsea & Westminster Hospital, London, UK;
Immediate Past-President, International AIDS Society
Claudia Cortes, University of Chile, Santiago, Chile; IAS Governing Council
09:45–09:50Introduction and aims
Anton Pozniak, and Claudia Cortes
09:50–10:02Landscape, service delivery, and pathways to affordability and access
Mitchell Warren, AIDS Vaccine Advocacy Coalition (AVAC), New York, NY, USA
10:02–10:14Examples and insights from Asia
Nittaya Phanuphak, Institute of HIV Research and Innovation, Bangkok, Thailand
10:14–10:26Examples and insights from Latin America
Beatriz Grinsztejn, FioCruz, Rio de Janeiro, Brazil
10:26–10:38Examples and insights from Africa
Kenly Sikwese, AfroCAB, Lusaka, Zambia
10:38–10:55Panel discussion and Q&A
All joined by Cissy Kityo, Joint Clinical Research Centre, Kampala, Uganda
10:55–11:00Summary and Close
Chairs
11:00–11:45HIV Clinical Challenges (II)
11:00–11:15Older people with well-controlled HIV have similar antibody and higher T-cell
responses after vaccination against SARS-CoV-2 compared to demographically
and lifestyle-comparable people without HIV
Myrthe Verburgh, Infectious Diseases, Amsterdam UMC, University of
Amsterdam, Amsterdam, Netherlands
11:15–11:30External validation of the Dat’AIDS score for predicting 5-year mortality among
elderly patients living with HIV in the Swiss HIV Cohort Study
Maxime Hentzien, HIV/AIDS Research Unit, Geneva University Hospitals,
Geneva, Switzerland
11:30–11:45COCOVIH study: impact of comorbidities on the over-mortality of people
living with HIV
François Prevoteau Du Clary, Centre de Santé Sexuelle, La Grave Hospital,
University Hospital Toulouse, Toulouse, France
11:45–12:30Lock Lecture
HIV Glasgow is honoured to have been chosen by the Royal College of Physicians and
Surgeons of Glasgow to present the Lock Lecture as part of the Scientific Programme
11:45–11:50Introduction
11:50–12:20PrEP vs PEP Interface: Where are We Now?
Sheena McCormack, Clinical Epidemiology, Imperial College London, UK
12:20–12:30Q&A
All
12:30–13:45Scientific Posters and Lunch
12:45–13:45Industry Symposium
13:45–15:00Response to Emerging Problems
In collaboration with the European AIDS Clinical Society (EACS)
Chairs:Tristan Barber, HIV Medicine, Ian Charleson Day Centre, Royal Free
Hospital, London, UK; and Chair, EACS Young Investigators (YING)
Georg Behrens, Department for Clinical Immunology and Rheumatology
Hannover Medical School, Hannover, Germany; and Chair,
EACS Guidelines Group
13:45–13:50Welcome and Introductions
Chairs
13:50–14:05Unified support framework to support HIV cascade of care for displaced
persons in Europe
Marta Vasylyev, Infectious Diseases, Astar Medical Center, Lviv, Ukraine; and
Co-chair, WAVE
14:05–14:20HIV Clinics and people living with HIV in times of epidemics: impact of
COVID-19 and MonkeyPox
Casper Rokx, HIV/Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands; and YING Scientific Committee
14:20–14:352022 update EACS Guidelines
Juan Ambrosioni, HIV/AIDS Unit and Infectious Disease Service, Hospital
Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain; and Co-ordinator,
EACS Guidelines
14:35–14:55Panel discussion and Q&A
All
14:55–15:00Wrap up and close
15:00–16:00Novel Therapeutics
15:00–15:25HIV and COVID-19 drug development: lessons learned for the next pandemic
Daniel Kuritzkes, Division of Infectious Diseases at Brigham and
Women’s Hospital, Boston, MA, USA
15:25–15:45bNABS for HIV
Marina Caskey, Laboratory of Molecular Immunology, The Rockefeller University,
New York, NY, USA
15:45–16:00VH3810109 (N6LS) reduces viremia across a range of doses in ART-naive
adults living with HIV: proof of concept achieved in the phase IIa
BANNER (207959, NCT04871113) study
Peter Leone, Clinical Development, ViiV Healthcare, Durham, NC, USA
16:00–17:15HIV Current Case Challenges: Interactive case study session
In collaboration with the International Antiviral Society-USA (IAS-USA)
Chairs:Roy Gulick, Infectious Diseases, Weill Cornell Medicine, New York, NY, USA
Chloe Orkin, Queen Mary University of London and Barts Health NHS
Trust, London, UK
16:00–16:05Welcome and Introductions
Chairs
16:05–16:25Heavily treatment-experienced case
Alexandra Calmy, Geneva, Switzerland
16:25–16:45HPV-related case
Deborah Konopnicki, Department of Infectious Diseases, Saint-Pierre University Hospital, and Université Libre de Bruxelles, Brussels, Belgium
16:45–17:05HIV and COVID-related case
Jose Arribas, La Paz Hospital, Madrid, Spain
17:05–17:15Key learnings summary and close
Chairs
17:15–17:30Scientific Posters and Coffee
17:30–18:30Industry Symposium